Plan to attend this special workshop to improve understanding and engagement through increased knowledge of available resources, and discuss of the value of care delivered and communication-based interventions for physician and patient interactions. The degree to which cancer caused financial problems was the strongest independent predictor of quality • of life when compared to various other factors including age, race, education, insurance status, and family income.
80% of medical oncologists believe it is important to be explicit about the potential financial impact of • treatment choices.
81% of academic medical oncologists agreed that out-of-pocket costs had the potential to influence • treatment recommendations, but only 30% reported changing treatment recommendations because of financial recommendations.
Patients reporting "a lot" of financial distress were more likely to be non-white, female, and younger than • 61 years of age. These patients were also more likely to have less than a four-year college education and a total household income lower than $35,000 per year.
If you are on Twitter or Facebook, follow us! Have the latest NRG Oncology news at your fingertips.
Be sure to join the conversation at our NRG Oncology Meeting by using our hashtag #NRG18 in your posts! See a listing of all of our studies on NRG Oncology's Protocol Table   OVeRVIew: The open-label, randomized, integrated phase II/III NRG-LU002 trial will compare maintenance systemic therapy combined with local consolidative therapy (LCT) to maintenance systemic therapy alone for patients with limited metastatic non-small cell lung cancer (NSCLC). The study aims to gauge if the addition of LCT improves progressionfree survival in phase II and overall survival in phase III.
AMeNDMeNt:
Initially, NRG-LU002 required participants on Arm 2 to receive docetaxel, gemcitabine, and pemetrexed (for non-squamous cases only). A recent amendment to the trial has added pembrolizumab and surgery as treatment options. 
Recently Activated

OVeRVIew:
The NRG-GU006 clinical trial will evaluate if the addition of apalutamide to salvage radiotherapy (SRT) will improve progression-free survival (PFS) when compared to SRT alone for men with postprostatectomy PSA recurrences. This biomarker-stratified, randomized, double-blind, placebo-controlled, phase II trial will assess the safety and efficacy of apalutamide as compared to SRT and will determine whether molecular stratification using the PAM50 gene expression test will identify subsets of patients with prostate cancer who derive the greatest benefit from anti-androgen therapy. If successful, the results of this study may be used to design a follow-up, phase III trial. Because this revision affects all protocols moving forward, it is important for nurses and data coordinators to be informed of and familiar with the changes. Changes to v5.0 include clarifications of grade descriptions, clarifications of definitions of AE terms, addition or subtraction of grades, and the addition or deletion of AE terms. As of April 1, 2018, death due to progressive disease should be reported as Grade 5 "Disease progression" in the system organ class (SOC) "General disorders and administration site conditions" in CTCAE v5.0.
A new feature of the CTCAE v5.0 is Navigation Notes. Although not all AE terms have a navigation note, the notes available are useful, relevant, and help the user choose the most accurate AE term. For example, the navigation note under "Dry eye" states: If corneal ulcer is present, grade under Eye disorders: Corneal ulcer. It will be important for the nurse or data coordinator to pay attention to these notes to help avoid incorrect reporting.
Version 5.0 includes approximately 60 new AE terms. Some of these additions reflect AEs commonly seen with immunotherapy drugs such as hypophysitis, thyroid stimulating hormone (TSH) increased, and hyperphosphatemia. For example, "TSH increased" has been added under the Investigations category. The only available grade is grade 1 defined as "TSH increased and no intervention initiated." A navigation note directs the user as follows: if intervention initiated or symptomatic report as endocrine disorder-hypothyroidism.
Other term additions permit greater AE reporting specificity. For example, the SOC Infection and Infestations now includes fungemia (fungus), bacteremia (bacteria), and virema (virus). Other important and common AEs included in v5.0 are: ascites, belching, generalized edema, thrush, nail changes, hair color change, and hair texture abnormal. Many of the new terms only have one grade available and signify that the event is present. Overall, additional terms facilitate consistent and accurate AE reporting. As noted in the NRG Oncology Semiannual Meeting agenda for Friday, July 13, 2018, you will see that the Protocol Support Committee (PSC) Clinical Trials Nurse Subcommittee meeting and the PSC Clinical Research Associate Subcommittee meeting, both scheduled from 7:00 am -9:00 am, have been indicated as "Open for first hour". Because the primary function of these meetings is to conduct business rather than to provide education, they have previously been designated as closed (*Sessions for Committee Members only). Some individuals who are not committee members have expressed interest in attending these meetings. This has been taken into consideration and the decision was made to have the meetings open to all who are interested for the first hour. The second hour will be closed to Committee Members only, to allow opportunity for nomination discussions, voting, etc.
We welcome your attendance for the first hour if either of these meetings interest you, with the understanding that they will focus on procedures and responsibilities rather than on education. If you have questions or would like additional information when deciding to register for either of these sessions, feel free to contact Cindy Licavoli, Chair of the CTN Subcommittee, at cynthia.licavoli@bjc.org, or Sharon Stockman, Chair of the CRA Subcommittee, at sharon-stockman@uiowa.edu.
The PSC will offer CTN and CRA education activities relevant to all levels of experience on Thursday July 12, 2018, 8am-4:30pm.
The morning session will include presentations by NRG Oncology Headquarters staff and the CTSU on topics that include an overview of CTCAE version 5.0, an update on the Rave-CTEP AERS integration, and the ins and outs of the Data Query Portal (DQP). Other presentations include an introduction to pathology and to genomic profiling, and an overview of changes to the AJCC Staging Manual. Judith M. Fannelli, an NRG Oncology CTN, will present "An Introduction to Reiki and More." Reiki is a Japanese technique for stress reduction and relaxation that also promotes healing administered by "laying on hands." Lunch will be provided during this presentation. CMEs will be provided for both the morning and afternoon sessions. Due to changes in ONS policy, nursing CEs are not available.
The PowerPoint slides for the morning presentations will be posted on the NRG Oncology website. Handouts will not be provided on site.
Publication Highlights
Analysis of Results from a Phase III trial for women with Ovarian cancer Following surgical cytoreduction
Results from a post-trial ad hoc analysis evaluating the level of concordance among surgeons' assessments of residual disease and pre-treatment computed tomography findings in a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. 100-104. doi: 10.1016 /j.conctc.2018 .03.003.Epub 2018 .
Full article
NRG Oncology Press Releases on Recent Publications
MGMt Promoter Methylation Associated with Improved survival for Patients with wHO Grade II Gliomas Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade, glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and treatment regiment. MGMT promoter methylation is an independent prognostic biomarker of high-risk, lowgrade glioma treated with temozolomide and radiation.
Read press release sBRt In addition to other recommendations, the working group recommended setting up a mechanism to track QOL compliance for each NRG Oncology institution. The goal of this strategy is to allow the PI and RAs at each institution to be more aware of their own institutional compliance rate with QOL forms so that they can communicate and work together to improve QOL compliance, as needed. The information will be itemized for each NRG Oncology study in which your institution participates, so that you can see where additional effort may be needed. We plan to distribute the new site reports in the fall. Because this is a new strategy, if you notice any discrepancies, please bring it to the attention of Francy Fonzi (at frances.fonzi@nsabp.org).
If your institutional QOl compliance rate is >80-90% at each time point, we applaud you and want to learn from your institutional experience. If it's <80%, please do a "deeper dive" to determine how this can be improved (for a particular study or overall). Once we begin distributing these reports, we will really need your help AsAP to address this issue immediately.
The QOL Compliance Working Group will be following up with individual institutional PIs as needed in this regard.
Although there are many compelling reasons to support this effort, perhaps the most important is that our patients want to be heard and to share their QOL experience so we can improve care for others in the future.
If you have any questions, please reach out to us. 
Do You Have Recommendations for Our Materials?
The NRG Oncology Communications Committee is always looking for suggestions for information and special achievements to include in the newsletter. Please send information about special achievements of NRG Oncology members or research teams, suggestions for future articles, and regular features you would like to see in future issues of the NRG Oncology Newsletter to info@nrgoncology.org
